Stat Consult

Asparaginase Erwinia chrysanthemi (Erwinaze)

January 26, 2012

Asparaginase Erwinia chrysanthemi is a component of a multiagent regimen for the treatment of acute lymphoblastic leukemia in patients with a hypersensitivity to Escherichia coli-derived asparaginase.
 

Brentuximab vedotin (Adcetris)

December 19, 2011

Brentuximab vedotin is an antibody-drug conjugate comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E.
 

Methylnaltrexone (Relistor)

October 19, 2011

Methylnaltrexone is a peripheral acting narcotic antagonist, opioid reversing agent. It is indicated for treatment of opioid-induced constipation.
 

Ipilimumab (Yervoy)

August 01, 2011

Ipilimumab is a recombinant, human cytotoxic T-lymphocyte antigen 4-blocking monoclonal antibody indicated for the treatment of unresectable or metastatic melanoma.
 

Oxaliplatin (Eloxatin)

April 18, 2011

Oxaliplatin is a platinum-containing antineoplastic agent used to treat lymph node positive colorectal carcinoma and metastatic colorectal cancer.
 

Fluorouracil IV (5-FU, Adrucil)

March 17, 2011

Fluorouracil is an antimetabolite antineoplastic agent indicated for colorectal, gastric, metastatic breast, metastatic colorectal, and pancreatic cancers.
 

Cisplatin (Platinol, Platinol-AQ)

February 01, 2011

Cisplatin is a platinum-containing, aklylating agent. It is often used in combination with other chemotherapy agents as well as monotherapy because of its relative lack of hematologic toxicity.
 

Erlotinib (Tarceva)

October 26, 2010

Erlotinib is a human epidermal growth factor receptor type 1/epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor approved for non-small cell lung cancer and pancreatic cancer.
 

Zoledronic acid (zoledronate, Zometa)

September 01, 2010

Zoledronic acid is a third-generation bisphosphonate prescribed to reduce pain from bony metastases, treat hypercalcemia of malignancy, and manage osteolytic lesions in multiple myeloma.
 

Doxorubicin

August 01, 2010

Doxorubicin is an anthracycline antibiotic that is used to treat lymphoblastic and acute myeloblastic leukemias, several types of cancer, Kaposi sarcoma related to AIDS, malignant lymphoma, soft tissue and osteogenic sarcomas, and Wilms tumor.
 

Two vital resources for melanoma management


Two myCME Webcasts, Management of Metastatic Melanoma and Management of Early Melanoma and Atypical Spitz Tumors, provide health care professionals with current and relevant research, treatment options, clinical data, guidance, and resources to optimize melanoma detection, management, patient care, and outcomes. Each Webcast offers 1.0 AMA PRA Category 1 CreditTM.

ONA Newsletters
Sign up today for one of our free newsletters:
  • Issue Preview
  • Latest CE
  • Reflections
  • Editor's choice
  • New on the Web

FEBRUARY 3 - 4
• 2012 Highlights of ASH in North America
New York, New York
• 2012 Highlights of ASH in North America
San Francisco, California
MARCH 3 - 4
• 2012 Highlights of ASH in Asia
Singapore, Singapore
MAY 3 - 6
• 37th Annual ONS Congress
New Orleans, Louisiana

Let us know what you are looking for in a new oncology nursing journal:

Click here to take our survey

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions